JUDGMENT

C. Hari Shankar, J.

Facts

The Plaint

1. The plaintiff claims to be the largest pharmaceutical company in India in 11 specialties, and the fourth largest Generic Pharmaceutical Company in the world, with a global turnover of Rs. 33,139 crores. Among other products, the plaintiff manufactures and markets pantoprazole, a well-known anti-acidity drug, under the brand name PANTOCID, in various variants, stand alone as well as in combination with other drugs. Where pantoprazole is to be found in combination with other drugs, appropriate suffixes attach to PANTOCID, such as PANTOCID-DSR, PANTOCID-L, and the like. The plaintiff holds registrations for the marks PANTOCID, PANTOCID-DSR, PANTOCID-IV and PANTOCID-L, under the Trade Marks Act, 1999, w.e.f. 19 February 1998, 30 August 2020, 8 September 2020 and 1 May 2020, respectively. Sales of the PANTOCID range of drugs have resulted in earnings to the plaintiff, during the years 2020-2021 and 2021-2022, of Rs. 386.8 crores and Rs. 513.63 crores. Para 11 of the plaint asserts that "the trademark PANTOCID was coined by the plaintiff's predecessor in the year 1998 and has been in use since the year 1999."

2. The plaintiff has asserted,